Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 0.00.
Virada para Prejuízo
O desempenho da empresa passou a ser negativo, com prejuízo anual mais recente de US$ .
Avaliação Justa
O PE mais recente da empresa é -0.14, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 31.80M ações, um aumento de 48.22% em relação ao trimestre anterior.
Mantido por James Simons
O Super Investidor James Simons possui 0.00 ações desta empresa.